SCHEMBL7971229

SCHEMBL7971229

O=C(O)[CH]c1cccc2[nH]ccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.46
AHR P35869 1/20 0.44
HPGD P15428 4/20 0.43
MEN1 O00255 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 1/20 0.42
CYP2A6 P11509 1/20 0.42
IMPDH2 P12268 1/20 0.42
TUBB4A P04350 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30285555 0.83 PARP1 (0.68) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL1322729 0.83 PARP1 (0.68) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL1322730 0.83 PARP1 (0.68) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL10923774 0.77 AHR (0.50) PARP1AHRMAPK1CYP2A6IMPDH2
SCHEMBL97761 0.77 CYP2A6 (0.57) AHRMEN1KMT2AMAPK1LMNA
SCHEMBL8583049 0.77 AKR1C3 (0.43) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL28168668 0.76 CYP2A6 (0.55) AHRMEN1KMT2AMAPK1LMNA
SCHEMBL23046878 0.74 PARP1 (0.50) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL15558969 0.74 AKR1C1 (0.47) PARP1AHRHPGDMEN1ALDH1A1
SCHEMBL10502860 0.74 MAPT (0.69) PARP1HPGDMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US claimed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP claimed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO claimed
US-6274715-B1 SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY ABBOTT LABORATORIES 2001-08-14 US disclosed
EP-0961776-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES Abbott Laboratories (US) 1999-12-08 EP disclosed
WO-1998030574-A1 TRICYCLIC ERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1998-07-16 WO disclosed